Prospects for bioreductive drug development

Bibliography

• DENEKAMP J: Endothelial cell attack as a novel ap-proach to cancer therapy. Cancer Topics (1986) 6:6–8.
   Google Scholar
• COLEMAN CN: Hypoxia in tumours: a paradigm for the approach to biochemical and physiologic heterogene-ity. J. Natl. Cancer Inst. (1988) 80: 310–317.
   PubMed Web of Science ®Google Scholar
• VAUPEL P, KALLINOWSKI F, OKUNIEFF P: Blood flow, oxygen and nutrient supply, and metabolic microen-vironment of human tumours: a review. Cancer Res. (1989) 49:6449–6465.
   PubMed Web of Science ®Google Scholar
• HELMINGER G, YUAN F, DELLIAN M, JAIN RK: Interstitial pH and p02 gradients in solid tumours in viva high resolution measurements reveal a lack of correlation. Nature Med. (1997) 3:177–182.
   PubMed Web of Science ®Google Scholar
• KENNEDY KA: Hypoxic cells as specific targets for che-motherapy. Anti Cancer Drug Des. (1987) 2:181–194.
   Google Scholar
• GRAEBER TG, OSMANIAN C, JACKS T et al.: Hypoxia me-diated selection of cells with diminished apoptotic po-tential in solid tumours. Nature (1996) 379:88–91.
   PubMed Web of Science ®Google Scholar
• KINZLER KW, VOGELSTEIN B: Life (and death) in a ma-lignant tumour. Nature (1996) 379:19–20.
   PubMed Web of Science ®Google Scholar
• THOMLINSON RH, GRAY LH: The histological structure of some lung cancers and the possible implications for radiotherapy. Br. J. Cancer (1955) 9:539–547.
   PubMed Web of Science ®Google Scholar
• BROWN JM, GIACCIA AJ: Tumour hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol (1994) 65:95–102.
   PubMed Web of Science ®Google Scholar
• CHAPLIN DJ, HORSMAN MR, AOKI DS: Nicotinamide, fluosol and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer (1991) 63:109–113.
   PubMed Web of Science ®Google Scholar
• BROWN JM: Hypoxic cell radiosensitizers. where next?Int. J. RadiaL Oncol. Biol. Phys. (1989) 16:987–993.
   PubMed Web of Science ®Google Scholar
• LIN AJ, COSBY LA, SHANSKY CW, SARTORELLI AC: Poten-tial bioreductive alkylating agents. Benzoquinone de-rivatives. J. Med. Chem. (1972) 15:1247–1252.
   PubMed Web of Science ®Google Scholar
• SARTORELLI AC: Therapeutic attack of hypoxic cells ofsolid tumours: presidential address. Cancer Res. (1988) 48:775–778.
   PubMedGoogle Scholar
• WORKMAN P, STRATFORD IJ: The experimental devel-opment of bioreductive drugs and their role in cancer therapy. Cancer Met. Rev. (1993) 12:73–82.
   PubMed Web of Science ®Google Scholar
• ROSS D, BEALL H, TRAVER RD et al.: Bioactivation of qui-nones by DT-diaphorase, molecular, biochemical and chemical studies. Oncol Res. (1994) 6:493–500.
   PubMed Web of Science ®Google Scholar
• ROSS D, BEALL HD, SIEGEL D, TRAVER RD, GUSTAFSON DL: Enzymology of bioreductive drug activation. Br. J. Cancer (1996) 74 (Suppl. XXVII):S1–S8.
   Google Scholar
• WORKMAN P: Enzyme directed bioreductive drug de-velopment revisited: a commentary on recent prog-ress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol. Res. (1994) 6:6–8.
   Google Scholar
• RAUTH AM, MARSHALL RS, KUEHL BL: Cellular ap-proaches to bioreductive drug mechanisms. Cancer Met. Rev. (1993) 12:153–164.
   PubMed Web of Science ®Google Scholar
• WARDMAN P, DENNIS MF, EVERETT SA et al.: Radicalsfrom one electron reduction of nitro compounds, aro-matic N-oxides and quinones: the kinetic basis for hy-poxia selective bioreductive drugs. Biochem. Soc. Symp. (1995) 61:171–194.
   PubMedGoogle Scholar
• WORKMAN P, WALTON MI: Enzyme directed bioreduc-tive drug development. In: Selective Activation of Drugs by Redox Processes. Adams GE, Breccia A, Fielden EM, Ward-man P (Eds.), Plenum Press, New York (1990):173–191.
   Google Scholar
• MALKINSON AM, SIEGEL D, FORREST GL et al: ElevatedDT-diaphorase activity and messenger RNA content in human non small cell lung carcinoma: relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res. (1992) 52:4752–4757.
   PubMed Web of Science ®Google Scholar
• PHILLIPS RM: Human DT-diaphorase as a candidate forenzyme directed bioreductive drug development. Drugs of the Future. (1996) 21:1247–1256.
   Google Scholar
• DENNY WA, WILSON WR, HAY MP: Recent develop-ments in the design of bioreductive drugs. Br. J. Cancer (1996) 74 (Suppl. XXVIO:532–538.
   Google Scholar
• SIIM BG, DENNY WA, WILSON WR: Nitro reduction as anelectronic switch for bioreductive drug activation. On-col. Res. (1997) 9:357–369.
   Google Scholar
• DENNY WA, WILSON WR: Bioreducible mustards - a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met. Rev. (1993) 12:135–151.
   PubMed Web of Science ®Google Scholar
• CONNORS TA: Bioreductive agents, hypoxic cells and therapy. Eur. J. Cancer. (1996) 32A:1833–1834.
   PubMed Web of Science ®Google Scholar
• POWIS G: Metabolism and reactions of quinoid anti-cancer agents. In: Anticancer Drugs: Reactive Metabolism and Drug Interactions. Powis G (Ed.), Pergamon Press, Ox-ford, UK (1990273–352.
   Google Scholar
• SARTORELLI AC, HODNICK WF, BELCOURT MF et al.: Mi-tomycin C: a prototype bioreductive drug. Oncol. Res. (1994) 6:501–508.
   PubMed Web of Science ®Google Scholar
• GIBSON NW, PHILLIPS RM, ROSS D: Mitomycin C. In: cancer chemotherapy and biological response modifiers. Pinedo HM, Longo DL, Chabner BA (Eds.), Annual 15, (199051–57.
   Google Scholar
• TOMASZ M, LIPMAN R: Reassignment of the guanine binding mode of reduced mitomycin C. Biochemistry (1986) 25:4337–4344.
   PubMed Web of Science ®Google Scholar
• TOMASZ M, LIPMAN R, CHOWDARY D et al.: Isolationand structure of a covalent cross link adduct between mitomycin C and DNA. Science (1987) 235:1204–1208.
   PubMed Web of Science ®Google Scholar
• BIZANEK R, MCGUINNESS BF, NAKANISHI K, TOMASZ M:Isolation and structure of an intrastrand cross-link ad-duct of mitomycin C and DNA. Biochemistry (1992) 31:3084–3091.
   PubMed Web of Science ®Google Scholar
• WARREN AJ, MACCUBBIN AE, HAMILTON JW: Detectionof mitomycin C-DNA adducts in vivo by 32P-postlabelling: time course for formation and removal of adducts and biochemical modulation. Cancer Res. (1998) 58:453–461.
   PubMed Web of Science ®Google Scholar
• PRITSOS CA, BRIGGS LA, GUSTAFSON DL: A new cellular target for mitomycin C: a case for mitochondrial DNA. Oncol. Res. (1997) 9:333–337.
   PubMed Web of Science ®Google Scholar
• KOMIYAMA T OKI T, INUI T: Activation of mitomycin C and quinone drug metabolism by NADPH cytochrome P450 reductase. J. Pharmacol Dyn. (1979) 2:407–410.
   Google Scholar
• PAN S, ANDREWS PA, GLOVER CJ, BACHUR NR: Reduc-tive activation of mitomycin C and mitomycin C me-tabolites catalysed by NADPH-cytochrome P450 reductase and xanthine oxidase. J. Biol. Chem. (1984) 259:959–966.
   PubMed Web of Science ®Google Scholar
• KEYES SR, FRACASSO PM, HEIMBROOK DC et al.: Role ofNADPH: cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res. (1984) 44:5638–5643.
   PubMed Web of Science ®Google Scholar
• BEGLEITER A, LEITH MK: Role of NAD(P)H: (quinoneacceptor) oxidoreductase (DT-diaphorase) in activa-tion of mitomycin C under acidic conditions. Mol. Pharmacol (1993) 44:5518–5525.
   Google Scholar
• GUSTAFSON DL, PRITSOS CA: Bioactivation of mitomy-cin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumours. J. Natl Cancer Inst. (1992) 84:1180–1185.
   PubMed Web of Science ®Google Scholar
• GUSTAFSON DL, PRITSOS CA: Kinetics and mechanismof mitomycin C bioactivation by xanthine dehydroge-nase under aerobic and hypoxic conditions. Cancer Res. (1993) 53:5470–5474.
   PubMed Web of Science ®Google Scholar
• GOEPTAR AR, GROOT EJ, SCHEERENS H et al.: Cytotox-icity of mitomycin C and adriamycin in freshly iso-lated rat hepatocytes: role of cytochrome P450. Cancer Res. (1994) 54:2411–2418.
   PubMed Web of Science ®Google Scholar
• HODNICK WF, SARTORELLI AC: Reductive activation ofmitomycin C by NADH:cytochrome bs reductase. Can-cer Res. (1993) 53:7483–7489.
   Google Scholar
• SPANS WICK VJ, CUMMINGS J, SMYTH JF: Enzymology ofmitomycin C metabolic activation in tumour tissue. Characterisation of a novel mitochondrial reductase. Biochem. Pharmacol (1996) 51:1623–1630.
   PubMed Web of Science ®Google Scholar
• SCHLAGER JJ, POWIS G: Mitomycin C is not metabolisedby but is an inhibitor of human kidney NAD(P)H:(qui-none acceptor) oxidoreductase. Cancer Chemother. Pharmacol (1988) 22:126–130.
   PubMed Web of Science ®Google Scholar
• WORKMAN P, WALTON MI, POWIS G, SCHLAGER JJ: DT-diaphorase: questionable role in mitomycin resis-tance, but a target for novel bioreductive drugs. Br. J. Cancer. (1989) 60:800–802.
   PubMed Web of Science ®Google Scholar
• SIEGEL D, GIBSON NW, PREUSCH PC, ROSS D: Metabo-lism of mitomycin C by DT-diaphorase: role in mito-mycin C induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. (1990) 50:7483–7489.
   PubMed Web of Science ®Google Scholar
• SIEGEL D, BEALL H, SENEKOWITSCH C et al: Bioreduc-tive activation of mitomycin C by DT-diaphorase. Bio-chemistry (1992) 31:7878–7885.
   Google Scholar
• SIEGEL D, BEALL HD, KASAI M, GIBSON NW, ROSS D: PHdependent inactivation of DT-diaphorase by mitomy-cin C and porfiromycin. Mol. Pharmacol. (1993) 44:1128–1134.
   PubMed Web of Science ®Google Scholar
• PRAKASH AS, BEALL HD, ROSS D, GIBSON NW: Sequenceselective alkylation and cross linking induced by mito-mycin C upon activation by DT-diaphorase. Biochemis-try (1993) 32:5518–5525.
   PubMed Web of Science ®Google Scholar
• BEGLEITER A, ROBOTHAM E, LEITH MK: Role of NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hy-poxia. Mol. Pharmacol (1993) 41:677–682.
   Web of Science ®Google Scholar
• PAN S-S, YU F, HIPSHER C: Enzymatic and pH modula-tion of mitomycin C induced DNA damage in mitomy-cin C resistant HCT 116 human colon cancer cells. Mol. Pharmacol (1993) 43:870–877.
   PubMed Web of Science ®Google Scholar
• SURESH KUMAR G, LIPMAN R, CUMMINGS J, TOMASZ M:Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic re-ductive activation of mitomycin C. Biochemistry (1997) 36:14128–14136.
   Google Scholar
• GRIFFITHS JR: Are cancer cells acidic? Br. J. Cancer (1991) 64:425–427.
   Web of Science ®Google Scholar
• FITZSIMMONS SA, WORKMAN P, GREVER M et al.: Reduc-tase enzyme expression across the National Cancer In-stitute tumour cell line panel: correlation with sensitivity to mitomycin C and E09. J. Natl. Cancer Inst. (1996) 88:259–269.
   PubMed Web of Science ®Google Scholar
• ROBERTSON N, HAIGH A, ADAMS GE, STRATFORD IJ: Factors affecting sensitivity to E09 in rodent and hu-man tumour cells in vitro: DT-diaphorase and hy-poxia. Eur. J. Cancer (1994) 30A:1013–1019.
   PubMed Web of Science ®Google Scholar
• DULHANTY AM, WHITMORE GF: Chinese hamster ovary cells resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res. (1991) 51:1860–1865.
   PubMed Web of Science ®Google Scholar
• MARSHALL RS, PATERSON MC, RAUTH AM: DT-diaphorase and mitomycin C sensitivity in nontrans-formed cell strains derived from members of a cancer prone family. Carcinogenesis (1991) 12:1175–1180.
   PubMed Web of Science ®Google Scholar
• O'DWYER PJ, PEREZ RP, YAO K-S, GODWIN AK, HAMIL-TON TC: Increased DT-diaphorase expression and cross resistance to mitomycin C in a series of cisplatin resistant human ovarian cancer cell lines. Biochem. Pharmacol (1996) 52:21–27.
   PubMed Web of Science ®Google Scholar
• BELCOURT MF, HODNICK WF, ROCKWELL S, SARTORELLI AC: Bioactivation of mitomycin C antibiotics and hy-poxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem. Pharmacol (1996) 51:1669–1678.
   PubMed Web of Science ®Google Scholar
• MIKAMI K, NAITO M, TOMIDA A et al: DT-diaphorase asa critical determinant of sensitivity to mitomycin C in human colon and gastric cell lines. Cancer Res. (1996) 56:2823–2826.
   PubMed Web of Science ®Google Scholar
• POWIS G, GASDASKA PY, GALLEGOS A, SHERILL K, GOODMAN D: Overexpression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively acti-vated anticancer drugs. AntiCancer Res. (1995) 15:1141–1146.
   PubMed Web of Science ®Google Scholar
• GUSTAFSON DL, BEALL HD, BOLTON EM, ROSS D, WAL-DREN CA: Expression of human NAD(P)H-quinone oxi-doreductase (DT-diaphorase) in Chinese hamster ovary cells - effect on the toxicity of antitumour qui-nones. Mol. Pharmacol (1996) 50:728–735.
   PubMed Web of Science ®Google Scholar
• PLUMB JA, WORKMAN P: Unusually marked hypoxic sensitisation to indoloquinone E09 and mitomycin C in a human colon tumour cell line that lacks DT-diaphorase activity. In. J. Cancer. (1994) 56:134–139.
   PubMed Web of Science ®Google Scholar
• BEALL HD, MULCAHY T, SIEGEL D et al.: Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorases. Cancer Res. (1994) 54:3196-3201. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• BELCOURT MF, HODNICK WF, ROCKWELL S, SARTORELLIAC: Differential toxicity of mitomycin C and porfiro-mycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P450) reductase. Proc. Natl. Acad. Sci. USA (1996) 93:456–460.
   PubMed Web of Science ®Google Scholar
• BROWN JM: SR 4233 (tirapazamine): a new anticancerdrug exploiting hypoxia in solid tumours. Br. J. Cancer (1993) 67:1163–1170.
   PubMed Web of Science ®Google Scholar
• ZEMAN EM, BROWN JM, LEMMON MJ, HIRST VK, LEE WW:SR 4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. RadiaL On-col. Biol. Phys. (1986) 12:1239–1242.
   PubMed Web of Science ®Google Scholar
• HANAUSKE AR, ROSS M, DEGEN D, HILSENBECK SG, VON HOFF DD: In vitro activity of the benzotriazene dioxide SR 4233 against human tumour colony forming units. Eur. J. Cancer (1993) 29A:423–425.
   PubMed Web of Science ®Google Scholar
• KOCH CJ: Unusual oxygen concentration dependence of toxicity of SR 4233, a hypoxic cell toxin. Cancer Res. (1993) 53:3992–3997.
   PubMed Web of Science ®Google Scholar
• PHILLIPS RM, CLAYTON MRK: Plateau phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tu-mours. Br. J. Cancer (1997) 75:196–201.
   PubMed Web of Science ®Google Scholar
• MASUNAGA S, ONO K, HORI H et al.: Effects of bioreduc-tive agents, tirapazamine and mitomycin C, on quies-cent cell populations in solid tumours, evaluated by micronucleus assay. Jpn. J. Cancer Res. (1997) 88:907–914.
   PubMedGoogle Scholar
• BAKER MA, ZEMAN EM, HIRST VK, BROWN JM: Metabo-lism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. (1988) 48:5947–5952.
   PubMed Web of Science ®Google Scholar
• COSTA AK, BAKER MA, BROWN JM, TRUDDELL JR: In vi-tro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide), a hypoxic cytotoxin and potential antitumour agent. Cancer Res. (1989) 49:925–929.
   PubMed Web of Science ®Google Scholar
• LADEROUTE KR, WARDMAN P, RAUTH AM: Molecularmechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR 4233). Biochem. Pharmacol (1988) 37:1487–1495.
   PubMed Web of Science ®Google Scholar
• LLOYD RV, DULING DR, RUMYANTSEVA GV, MASON RP, BRIDSON PK: Microsomal reduction of 3-amino-1,2,4-benzotriazene 1,4-dioxide to a free radical. Mol. Phar-macol (1991) 40:440–445.
   PubMed Web of Science ®Google Scholar
• ELWELL JH, SIIM BG, EVANS JW, BROWN JM: Adaptation of human tumour cells to tirapazamine under aerobic conditions: implications of increased antioxidant en-zyme activity to mechanism of aerobic cytotoxicity. Biochem. Pharmacol (1997) 54:249–257.
   PubMed Web of Science ®Google Scholar
• RILEY RJ, HEMINGWAY SA, GRAHAM MA, WORKMAN P:Initial characterisation of the major mouse cyto-chrome P450 enzymes involved in the reductive me-tabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazene-1,4-di-N-oxide (tira-pazamine, SR 4233, WIN 59075). Biochem. Pharmacol (1993) 45:1065–1077.
   PubMed Web of Science ®Google Scholar
• WALTON MI, WORKMAN P: Enzymology of the reduc-tive bioactivation of SR 4233. A novel benzotriazene di-N-oxide hypoxic cell cytotoxin. Biochem. Pharmacol (1990) 39:1735–1742.
   Google Scholar
• CAHILL A, JENKINS TC, WHITE IN: Metabolism of 3-amino-1,2,4-benzotriazene-1,4-dioxide (SR 4233) by purified DT-diaphorase under aerobic and anaerobic conditions. Biochem. Pharmacol. (1993) 45:321–329.
   PubMed Web of Science ®Google Scholar
• WALTON MI, WOLF CR, WORKMAN P: The role of cyto-chrome P450 and cytochrome P 450 reductase in the reductive bioactivation of the novel benzotriazene di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazene-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem. Pharmacol (1992) 44:251–259.
   PubMed Web of Science ®Google Scholar
• JONES GD, WEINFIELD M: Dual action of tirapazaminein the induction of DNA strand breaks. Cancer Res. (1996) 56:1584–1590.
   PubMed Web of Science ®Google Scholar
• FITZSIMMONS SA, LEWIS AD, RILEY RJ, WORKMAN P: Re-duction of 3-amino-1,2,4-benzotriazene-1,4-di-N-oxide (tirapazamine, WIN 59075, 5114233) to a DNA damaging species: a direct role for NADPH: cytochrome P450 oxi-doreductase. Carcinogenesis (1994) 15:1503–1510.
   PubMed Web of Science ®Google Scholar
• PATTERSON AV, SAUNDERS MP, CHINJE EC et al.: Over-expression of human NADPH:cytochrome c (P450) re-ductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer (1997) 76:1338–1347.
   PubMed Web of Science ®Google Scholar
• RILEY RJ, WORKMAN P: Enzymology of the reduction ofthe potent benzotriazene-di-/V-oxide hypoxic cell cyto-toxin SR 4233 (WIN 59075) by NAD(P)H: (quinone ac-ceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem. Pharmacol (1992) 43:167–174.
   Google Scholar
• BIEDERMANN KA, WANG J, GRAHAM RP, BROWN JM: SR4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Can-cer (1991) 63:358–362.
   PubMed Web of Science ®Google Scholar
• GIACCIA AJ, BIEDERMANN KA, TOSTA LM, et al: Charac-terisation of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233. Int. J. Radiat. Oncol. Biol. Phys. (1992) 22:681–684.
   PubMed Web of Science ®Google Scholar
• HERSHER LL, KRISHNA MC, COOK JA et al: Protection against SR 4233 (tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Int. J. RadiaL Oncol Biol. Phys. (1994) 30:879–885.
   Web of Science ®Google Scholar
• OLIVE PL: Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I, Ti-rapazamine. Br. J. Cancer (1995) 71:529–536.
   PubMed Web of Science ®Google Scholar
• BROWN JM, LEMMON MJ: SR 4233: a tumour specific ra-diosensitizer active in fractionated radiation regimes. Radiother. Oncol (1991) 20 (Suppl 1):151–156.
   PubMedGoogle Scholar
• BROWN JM, LEMMON MJ: Tumour hypoxia can be ex-ploited to preferentially sensitize tumours to fraction-ated irradiation. Int. J. RadiaL Oncol. Biol. Phys. (1991) 20:457–461.
   Web of Science ®Google Scholar
• BROWN JM, LEMMON MJ: Potentiation by the hypoxiccytotoxin SR 4233 of cell killing produced by fraction-ated irradiation of mouse tumours. Cancer Res. (1990) 50:7745–7749.
   PubMed Web of Science ®Google Scholar
• SHIBATA T, SHIBAMOTO Y, SASAI K et al.: Comparisonof in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn. J. Cancer Res. (1996) 87:98–104.
   PubMedGoogle Scholar
• DORIE MJ, MENKE D, BROWN JM: Comparison of the en-hancement of tumour responses to fractionated irra-diation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int. J. Radiat. Oncol Phys. (1994) 28:145–150.
   PubMed Web of Science ®Google Scholar
• MCKEOWN SR, FRIERY OP, MCINTYRE IA et al.: Evi-dence for a therapeutic gain when AQ4N or tira-pazamine is combined with radiation. Br. J. Cancer (1996) 74 (Suppl. 27):S39–S42.
   Google Scholar
• OLIVE PL, BANATH JP, DURAND RE: Detection of sub-populations resistant to DNA damaging agents in spheroids and murine tumours. Mutat. Res. (1997) 375: 157–165.
   PubMed Web of Science ®Google Scholar
• SIIM BG, MENKE DR, DORIE MJ, BROWN JM: Tira-pazamine induced cytotoxicity and DNA damage in transplanted tumours: relationship to tumour hy-poxia. Cancer Res. (1997) 14:2922–2928.
   Google Scholar
• LANGMUIR VK, ROOKER JA, OSEN M, MENDONCA HL,LADEROUTE KR: Synergistic interaction between tira-pazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res. (1994) 54:2845–2847.
   PubMed Web of Science ®Google Scholar
• DORIE MJ, BROWN JM: Tumour specific, schedule de-pendent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. (1993) 53:4633–4636.
   PubMed Web of Science ®Google Scholar
• HOLDEN SA, TEICHER BA, ARA G, HERMAN TS, COLEMANCN: Enhancement of alkylating agent activity by SR 4233 in the FSaIIC murine fibrosarcoma. J. Natl. Cancer Inst. (1992) 84:187–193.
   PubMed Web of Science ®Google Scholar
• SIEMANN DW: The in situ tumour response to combi-nations of cyclophosphamide and tirapazamine. Br. J. Cancer. (1996) 74 (Suppl. XXVII): S65–S69.
   Google Scholar
• LARTIGAU E, GUICHARD M: The effect of tirapazamine (SR 4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br. J. Cancer (1996) 73:1480–1485.
   PubMed Web of Science ®Google Scholar
• DORIE MJ, BROWN JM: Modification of the antitumour activity of chemotherapeutic drugs by the hypoxic agent tirapazamine. Cancer Chemother. Pharmacol. (1997) 39:361–366.
   PubMed Web of Science ®Google Scholar
• DURAND RE, OLIVE PL: Physiologic and cytotoxic ef-fects of tirapazamine in tumour bearing mice. Radiat. Oncol. Invest. (1997) 5:213–219.
   PubMedGoogle Scholar
• SENAN S, RAMPLING R, GRAHAM MA et al.: Phase I and pharmacokinetic study of tirapazamine (SR 4233) ad-ministered every three weeks. Clin. Cancer Res. (1997) 3:31–38.
   PubMed Web of Science ®Google Scholar
• DOHERTY N, HANCOCK SL, KAYE SB et al.: Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation . Int. J. Radiat. Oncol Biol. Phys. (1994) 29:379–382.
   PubMed Web of Science ®Google Scholar
• JOHNSON CA, KILPATRICK D, VON ROEMELING R et al.: Phase I trial of tirapazamine in combination with cis-platin in a single dose every 3 weeks in patients with solid tumours. J. Clin. Oncol (1997) 15:773–780.
   Google Scholar
• AGHAJANIAN C, BROWN C, O'FLAHERTY C et al.: Phase I study of tirapazamine and cisplatin in patients with re-current cervical cancer. Gynecol Oncol. (1997) 67:127–130.
   Google Scholar
• BEDIKIAN AY, LEGHA SS, ETON 0 et al.: Phase II trial of tirapazamine combined with cisplatin in chemother-apy of advanced malignant melanoma. Ann. Oncol. (1997) 8:363–367.
   Google Scholar
• MILLER VA, NG KK, GRANT SC et al.: Phase II study of the combination of the novel bioreductive agent, tira-pazamine, with cisplatin in patients with advanced non-small cell lung cancer. Ann. Oncol. (1997) 8:1269–1271.
   PubMed Web of Science ®Google Scholar
• GATINEAU M, RIXE 0, REY A, TRANDAFIR L, LE CHEVA-LIER T: Phase I/II study of the addition of tirapazamine (TIRA) to cisplatin (CDDP)/navelbine (NVB) in pa-tients with inoperable non small cell lung cancer. Eur. J. Cancer (1997) 33:S249.
   Google Scholar
• BOYER MJ: Bioreductive drugs: a clinical update. Oncol Res. (1997) 9:391–395.
   PubMed Web of Science ®Google Scholar
• OOSTVEEN EA, SPECKAMP WN: Mitomycin analogues I. Indoloquinones as potent bis-alkylating agents. Tetra-hedron. (1987) 43:255–262.
   Web of Science ®Google Scholar
• HENDRIKS HR, PIAZO PE, BERGER DP et al: E09: a novel bioreductive alkylating indoloquinone with preferen-tial solid tumour activity and lack of bone marrow tox-icity in preclinical models. Eur. J. Cancer (1993) 29A:897–906.
   PubMed Web of Science ®Google Scholar
• SMITKAMP-WILMS E, HENDRIKS HR, PETERS GJ: Devel-opment, pharmacology, role of DT-diaphorase and prospects of the indoloquinone E09. Gen. Pharmacol (1996) 27:421–429.
   PubMedGoogle Scholar
• WALTON MI, SMITH PJ, WORKMAN P: The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent E09. Cancer Com-mun. (1991) 3:199–206.
   Google Scholar
• MALIEPAARD M, WOLF A, GROOT SE, DE MOL NJ, JANS-SEN LHM: Indoloquinone E09: DNA interstrand cross linking upon reduction by DT-diaphorase or xanthine oxidase. Br. J. Cancer (1995) 71:836–839.
   PubMed Web of Science ®Google Scholar
• BAILEY SM, WYATT MD, FRIEDLOS F et al.: Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross link-ing and sequence selectivity of the bioreductive anti-tumour agent E09. Br. J. Cancer. (1997) 76:1596–1603.
   Google Scholar
• SMITKAMP-WILMS E, PETERS GJ, PINEDO HM, VAN ARK-OTTE J, GIACCONE G: Chemosensitivity to the indolo-quinone E09 is correlated with DT-diaphorase activity © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6) and gene expression. Biochem. Pharmacol (1994) 47:1325–1332.
   Google Scholar
• COLLARD J, MATTHEW AM, DOUBLE JA, BIBBY MC: E09: relationship between DT-diaphorase levels and re-sponse in vitro and in vivo. Br. J. Cancer (1995) 71:1199–1203.
   PubMed Web of Science ®Google Scholar
• PLUMB JA, GERRITSEN M, WORKMAN P: DT-diaphorase protects cells from the hypoxic cytotoxicity of indolo-quinone E09. Br. J. Cancer. (1994) 70:1136–1143.
   PubMed Web of Science ®Google Scholar
• BEGLEITER A, LEITH MK, CURPHEY TJ: Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase anti-tumour activity of bioreductive agents. Br. J. Cancer (1996) 74 (Suppl. XXVII):S9–S14.
   Google Scholar
• PLUMB JA, GERRITSEN M, MILROY R, THOMSON P, WORKMAN P: Relative importance of DT-diaphorase and hypoxia in the bioactivation of E09 by human lung tumour cell lines. Int. J. Radia. Oncol. Biol. Phys. (1994) 29:295–299.
   PubMed Web of Science ®Google Scholar
• BAILEY SM, LEWIS AD, PATTERSON LH, FISHER GR: Free radical generation following reduction of E09: in-volvement in cytotoxicity. Br. J. Cancer. (1993) 67 (Suppl. XX):8
   Google Scholar
• BUTLER J, SPANSWICK VJ, CUMMINGS J: The autooxida-tion of the reduced forms of E09. Free Rad. Res. (1996) 25:141–148.
   PubMed Web of Science ®Google Scholar
• BAILEY SM, LEWIS AD, WORKMAN P: Involvement of NADPH:cytochrome P450 reductase in activation of E09. Br. J. Cancer (1994) 69(Suppl. XXI):57.
   Google Scholar
• SAUNDERS M. JAFFAR M, PATTERSON AV et al: Structural requirements for E09 toxicity and dependence on P450 reductase for activation. Br. J. Cancer (1996) 73:27.
   Google Scholar
• SCHELLENS JHM, PLANTING AST, VAN ACKER BAC et al.: Phase I and pharmacologic study of the novel indolo-quinone bioreductive alkylating cytotoxic drug E09. J. Natl. Cancer Inst. (1994) 86:906–912.
   Google Scholar
• DIRIX LY, TONNESEN F, CASSIDY J et al.: E09 Phase II study in advanced breast, gastric, pancreatic and colo-rectal carcinoma by the EORTC Early Clinical Studies Group. Eur. J. Cancer (1996) 32A:2019–2022.
   PubMed Web of Science ®Google Scholar
• PAVLIDIS N, HANAUSKE AR, GAMUCCI T et al: A random-ised Phase II study with two schedules of the novel in-doloquinone E09 in non small cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann. Oncol (1996) 7:529–531.
   PubMed Web of Science ®Google Scholar
• SEGURA-AGUILAR J, CREMADES A, LLOMBART-BOSH A et al.: Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours. Carcinogenesis (1994) 15: 1631–1636.
   PubMed Web of Science ®Google Scholar
• PHILLIPS RM, LOADMAN PM, CRONIN BP: Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br. J. Cancer (1998):( in press).
   Google Scholar
• MATTHEW AM, PHILLIPS RM, BIBBY MC: Optimisation of E09 activity in human tumour xenografts. Ann. Oncol (1996) 7 (Suppl. 1):131.
   Google Scholar
• GARDINER J, RITCHIE AA, CUMMINGS J, JODRELL DI, SMYTH J: Encapsulation of the indoloquinone E09 as a potential therapy for colorectal liver metastases. Br. J. Cancer. (1996) 73 (Suppl. XXVI):28.
   Google Scholar
• SEYMOUR LW, SOYEZ H, DE MARRE A, SHOAIBI MA, SCHACHT EH: Polymeric prodrugs of mitomycin C de-signed for tumour tropism and sustained activation. Anti. Cancer Drug. Des. (1996) 11:351–365.
   Google Scholar
• PHILLIPS RM: Bioreductive activation of a series of ana-logues of 5-aziridino-3-hydroxymethy1-1-methy1-241H-indole-4,7-dione] propenol (E09) by human DT-diaphorase. Biochem. Pharmacol (1996) 52:1711–1718.
   PubMed Web of Science ®Google Scholar
• BAILEY SM, SUGGET N, WALTON MI, WORKMAN P: Struc-ture activity relationships for DT-diaphorase reduc-tion of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones. Int. J. RadiaL Oncol Biol. Phys. (1992) 22:649–653.
   Web of Science ®Google Scholar
• JAFFAR M, NAYLOR MA, ROBERTSON N et al.: 5-substituted analogues of 3-hydroxymethy1-5-aziridiny1-1-methyl-241H-indole-4,7-dionelprop-2-en-l-ol (E09, NSC 382459) and their regioisomers as hypoxia selective agents: Structure- cytotoxicity in vi-tro. AntiCancer Drug. Des. (1998) 13:105–124.
   PubMedGoogle Scholar
• NAYLOR MA, JAFFAR M, NOLAN J et al.: 2 - Cyclopropylindoloquinones and their analogues as bioreductively activated antitumour agents: structure activity in vitro and efficacy in vivo. J. Med. Chem. (1997) 40:2335–2346.
   PubMed Web of Science ®Google Scholar
• KHAN AH, DRISCOLL JS: Potential central nervous sys-tem antitumour agents aziridinylbenzoquinones 1. J. Med. Chem. (1976) 19:313–317.
   PubMed Web of Science ®Google Scholar
• MARAL J, POISSON M, PERTUISET BF et al.: Phase II evaluation of diaziquone (CI-904, AZQ) in the treat-ment of human malignant glioma. J. Neuro. Oncol (1985) 3:245–249.
   PubMed Web of Science ®Google Scholar
• SIEGEL D, GIBSON NW, PREUSCH PC, ROSS D: Metabo-lism of diaziquone by NAD(P)H: (quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. (1990) 50:7293–7300.
   PubMed Web of Science ®Google Scholar
• GIBSON NW, HARTLEY JA, BUTLER J, SIEGEL D, ROSS D: Relationship between DT-diaphorase mediated me-tabolism of a series of aziridinylbenzoquinone and DNA damage and cytotoxicity. Mol. Pharmacol (1992) 42:531–536.
   PubMed Web of Science ®Google Scholar
• LEE C-S, HARTLEY JA, BERARDINI MD eta].: Alteration in DNA cross linking and sequence selectivity of a series of aziridinyl-benzoquinones after enzymatic reduc-tion by DT-diaphorase. Biochemistry (1992) 31:3019-3025. 144. BEALL HD, MURPHY AM, SIEGEL D et al.: Nicotinamide adenine dinucleotide (phosphate):quinone oxidore-ductase (DT-diaphorase) as a target for bioreductive antitumour quinones: quinone cytotoxicity and selec-tivity in human lung and breast cancer cell lines. Mol Pharmacol (1995) 48:499-504. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• SUN X, ROSS D: Quinone induced apoptosis in human colon adenocarcinoma cells via DT-diaphorase medi-ated bioactivation. Chem. Biol. Interact. (1996) 100:267–276.
   PubMed Web of Science ®Google Scholar
• PHILLIPS RM, DE LA CRUZ A, GIBSON NW: Relationship between DT-diaphorase activity and chemosensitivity in vitro to analogues of mitomycin C and diaziquone. Br. J. Cancer (1994) 69 (Suppl. XXVI):59.
   Google Scholar
• CUMMINGS J, LANGDON SP, ROSS D, BUTLER J: Antitu-mour activity of the novel bioreductive MeDZQ against non small cell lung cancer xenografts. Ann. Oncol (1996) 7\(Suppl. 1):129.
   Google Scholar
• GRAHAM MA, KING LH, WORKMAN P et al.: Identifica-tion of cyt P450 2C8 as the major human P450 isoform involved in the bioreduction of the novel anthraqui-none di-N-oxide, AQ4N. Br. J. Cancer (1993) 67 (Suppl. XX):9
   Google Scholar
• PATTERSON LH: Rationale for the use of aliphatic N-o-xides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Can-cer Met. Rev. (1993) 12:119–134.
   PubMed Web of Science ®Google Scholar
• PATTERSON LH, CRAVEN MR, FISHER GR, TEESDALE-SPITTLE P: Aliphatic amine /V-oxides of DNA binding agents as bioreductive drugs. Oncol. Res. (1995) 6:533–538.
   Web of Science ®Google Scholar
• KRUPSKI G, KIEFER F, WEIBEL FJ: Varaibility in the ex-pression of xenobiotic metabolising enzymes during the growth cycle of rat hepatoma cells. Xenobiotica (1985) 15:781–787.
   PubMed Web of Science ®Google Scholar
• WILSON WR, DENNY WA, PULLEN SM et al.: Tertiary amine /V-oxides as bioreductive drugs: DACA N-oxide, nitracrine /V-oxide and AQ4N. Br. J. Cancer (1996) 74 (Suppl XXVII):S43–S47.
   Google Scholar
• MCKEOWN SR, HEJMADI MV, MCINTYRE IA, MCALEER JJA, PATTERSON LH:AQ4N: an alkylaminoanthraqui-none /V-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br. J. Cancer (1995) 72:76–81.
   PubMed Web of Science ®Google Scholar
• HEJMADI MV, MCKEOWN SR, FRIERY OP etal.: DNA dam-age following combination of radiation with the biore-ductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br. J. Cancer. (1996) 73:499–505.
   Google Scholar
• DACHS GU, STRATFORD IJ: The molecular response of mammalian cells to hypoxia and the potential for ex-ploitation in cancer therapy. Br. J. Cancer (1996) 74 (Suppl. XXVII):5126–5132.
   Google Scholar
• DACHS GU, PATTERSON AV, FIRTH JD et al.: Targeting gene expression to hypoxic tumour cells. Nature Med. (1997) 3:515–520.
   PubMed Web of Science ®Google Scholar
• CONNORS TA: The choice of prodrugs for gene-directed enzyme prodrug therapy of cancer. Gene Ther. (1995) 2:702–709.
   PubMed Web of Science ®Google Scholar
• WARE DC, PALMER BD, WILSON WR, DENNY WA: Hypoxia-selective antitumour agents 7. Metal com-plexes of aliphatic mustards are a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt (III) complexes of bidentate mus-tards. J. Med. Chem. (1993) 36:1839–1846.
   Google Scholar
• WILSON WR, MOSELEN JW, CLIFFE SC, DENNY WA, WARE DC: Exploiting tumour hypoxia through release of dif-fusible cytotoxins: the cobalt (III) nitrogen mustard complex SN 24771. Int. J. Radial Oncol. Biol. Phys. (1994) 29
   Google Scholar
• ANDERSON RF, DENNY WA, WARE DC, WILSON WR: Pulse radiolysis studies on the hypoxia selective toxic-ity of a cobalt-mustard complex. Br. J. Cancer (1996)74 (Suppl XXVII):S48–S51.
   Google Scholar
• WARE DC, PALMER HR, PRUIJN FB et al.: Bis(dial-kyficlithiocarbamato cobalt (III) complexes of biden-tate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. Anti Cancer Drug Des. (1998) 13:81–104.
   Google Scholar
• SUTHERLAND RM: Selective chemotherapy of non-cycling cells in an in vitro tumour model. Cancer Res. (1974) 34:3501–3503.
   PubMed Web of Science ®Google Scholar
• ADAMS GE, STRATFORD IJ: Hypoxia mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overwiew. Biochem. Pharmacol (1988) 35:71–76.
   Web of Science ®Google Scholar
• STRATFORD IJ, O'NEIL P, SHELDON P et al.: RSU 1069, a nitroimidazole containing an aziridine group . Biore-duction greatly enhances cytotoxicity under hypoxic conditions. Biochem. Pharmacol (1986) 35:105–109.
   Google Scholar
• STRATFORD IJ, WALLING JM, SILVER ARJ: The differen-tial cytotoxicity of RSU 1069: cell survival studies indi-cating interaction with DNA as a possible mode of action. Br. J. Cancer (1986) 53:339–344.
   PubMed Web of Science ®Google Scholar
• O'NEILL P, MCNEIL SS, JENKINS TC: Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU 1069 and RSU 1131. Bio-chem. Pharmacol (1987) 36:1787–1792.
   PubMed Web of Science ®Google Scholar
• MOSELEN JW, HAY MP, DENNY WA, WILSON WR: N- [2- (2-methyl-5-nitroimidazolyfibutanamide (NSC 639862), a bisnitroimidazole with enhanced selectiv-ity as a bioreductive drug. Cancer Res. (1995) 55:574–580.
   PubMed Web of Science ®Google Scholar
• OVERGAARD J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumours. Oncol. Res. (1994) 6:509–518.
   PubMed Web of Science ®Google Scholar
• COLE S, STRATFORD IJ, ADAMS GE, FIELDEN EM, JENKINS TC: Dual-function 2-nitroimidazoles as hypoxic cell ra-diosensitizers and bioreductive cytotoxins: in vivo evaluation against KHT murine sarcomas. Radial Res. (1990) 124:S38–S43.
   PubMed Web of Science ®Google Scholar
• COLE S, STRATFORD IJ, BOWLER J et al.: Oral (p.o.) dos-ing with RSU 1069 or RB 6145 maintains their potency as hypoxic radiosensitizers and cytotoxins but re-duces systemic toxicity compared with parenteral (ip.) administration in mice. Int. J Radial Oncol. Phys. (1991) 21:387–395.
   Google Scholar
• COLE S, STRATFORD IJ, FIELDEN EM et al.: Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6) 130908). Int. J. RadiaL Oncol. Biol. Phys. (1992) 22:545–548.
   Google Scholar
• ADAMS GE, STRATFORD IJ: Bioreductive drugs for can-cer therapy: the search for tumour specificity. Int. J. Ra-diat. Oncol. Biol. Phys. (1994) 29:231–238.
   PubMed Web of Science ®Google Scholar
• HAY MP, DENNY WA, WILSON WR: Nitroimidazole-based 'extruded mustards' designed as reductively ac-tivated hypoxia-selective cytotoxins. Anti Cancer Drug Des. (1996) 11:383–402.
   Google Scholar
• STONE HB, BROWN JM, PHILLIPS TL, SUTHERLAND RM: Oxygen in human tumours: correlations between methods of measurement and response to therapy. Ra-diat. Res. (1993) 136:422–434.
   PubMed Web of Science ®Google Scholar
• RAMPLING R, CRUICKSHANK G, LEWIS AD, FITZSIM-MONS S, WORKMAN P: Direct measurement of p02 dis-tribution and bioreductive enzymes in human malignant brain tumours. Int. J. RadiaL Oncol. Biol. Phys. (1994) 29:427–431.
   Google Scholar
• HODGKISS RJ, PARRICK J, PORSSA M, STRATFORD MRL: Bioreductive markers for hypoxic cells: 2-nitroimidazoles with biotinylated substituents. J. Med. Chem. (1994) 37:4352–4356.
   PubMed Web of Science ®Google Scholar
• KOCH CJ, GIANDOMENICO AR, IYENGAR CWL: Biore-ductive metabolism of AF-2 [2(2-fury1)-3-(5-nitro-2-furyfiacrylamide] combined with 2-nitroimidazoles: implications for use as hypoxic cell markers. Biochem. Pharmacol (1993) 46:1029–1036.
   PubMed Web of Science ®Google Scholar
• MAXWELL RJ, WORKMAN P, GRIFFITHS JR: Demonstra-tion of tumour selective retention of fluorinated probe by 19F magnetic resonance spectroscopy in vivo. In. J. RadiaL Oncol. Biol. Phys. (1988) 16:925–929.
   Web of Science ®Google Scholar
• URTASUN RC, PARLIMENT MB, MCEWAN AJ et al.: Meas-urement of hypoxia in human tumours by non inva-sive spect imaging of iodoazomycin arabinoside. Br. J. Cancer. (1996) 74 (Suppl XXVII) :S209–5212.
   Google Scholar
• NORDSMARK M, KELLER J, NIELSEN OS, LUNDORF E, OVERGAARD J: Tumour oxygenation assessed by pola-rographic needle electrodes and bioenergentic status by P-31 magnetic resonance spectroscopy in human soft tissue tumours. Acta Oncologica. (1997) 36:565–571.
   PubMed Web of Science ®Google Scholar
• OLIVE PL, BANATH J, DURAND RE: Heterogeneity in ra-diation induced DNA damage and repair in tumour and normal cells measured using the 'comet' assay. Ra-diat. Res. (1990) 122:86–94.
   PubMed Web of Science ®Google Scholar
• OLIVE PL, DURAND RE, LERICHE J, JACKSON SM: Gel elec-trophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res. (1993) 53:733–736.
   PubMed Web of Science ®Google Scholar
• RALEIGH JA, LA DINE JK, CLINE JM, THRALL DE: An en-zyme linked immunosorbent assay for hypoxia marker binding in tumours. Br. J. Cancer (1994) 69:66–71.
   PubMed Web of Science ®Google Scholar
• CHERIE A, WALLACE S, YANG DJ et al: Development of new markers for hypoxic cells: [1311]Iodomisonida-zole and [1311]Iodoerythronitroimidazole. J. Drug Tar-get. (1996) 4:31–39.
   PubMed Web of Science ®Google Scholar
• WEBSTER L, HODGKISS, RJ, WILSON GD: Cell cycle dis-tribution of hypoxia and progression of hypoxic tu-mour cells in vivo. Br. J. Cancer. (1998) 77:227–234.
   PubMed Web of Science ®Google Scholar
• HODGKISS RJ, JONES G, LONG A et al: Flow cytometric evaluation of hypoxic cells in solid experimental tu-mours using fluorescence immunodetection. Br. J. Cancer (1991) 63:119–125.
   PubMed Web of Science ®Google Scholar
• CHAPMAN JD, BAER K, LEE J: Characteristics of the metabolism-induced binding of misonidazole to hy-poxic mammalian cells. Cancer Res. (1983) 43:936–942.
   Google Scholar
• MCMANUS ME, LANG MA, STUART K, STRONG J: Activa-tion of misonidazole by rat liver microsomes and puri-fied NADPH-cytochrome c reductase. Biochem. Pharmacol (1982) 31:547–552.
   PubMed Web of Science ®Google Scholar
• ABOAGYE EO, LEWIS AD, JOHNSON A et al.: The novel fluorinated 2-nitroimidazole hypoxia probe SR 4554: reductive metabolism and semiquantitative localisa-tion in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopy. Br. J. Cancer (1995) 72:312–318.
   PubMed Web of Science ®Google Scholar
• ABOAGYE EO, LEWIS AD, GRAHAM MA et al.: The phar-macokinetics, bioavailability and biodistribution of a rationally designed 2-nitroimidazole hypoxia probe SR 4554. Anti Cancer Drug Des. (1996) 11:231–242.
   Google Scholar
• ABOAGYE EO, MAXWELL RJ, KELSON AB et al: Preclini-cal evaluation of fluorinated 2-nitroimidazole N-(2-hydroxy-3,3, 3-trifluoro-propy1)-2-(2-nitro-1-imidazolyfiacetamide (SR-4554) as a probe for the measurement of tumour hypoxia. Cancer Res. (1997) 57: 3314–3318.
   PubMed Web of Science ®Google Scholar
• ABOAGYE EO, MAXWELL RJ, HORSMAN MR et al.: The re-lationship between tumour oxygenation determined by oxygen electrode measurement and magnetic reso-nance spectroscopy of the fluorinated 2-nitroimidazole SR-4554. Br. J. Cancer (1998) 77:65–70.
   PubMed Web of Science ®Google Scholar
• LORD EM, HARWELL L, KOCH CJ: Detection of hypoxic cells by monoclonal antibody recognising 2-nitroimidazole adducts. Cancer Res. (1993) 53:5271–5276.
   Google Scholar
• KOCH CJ, EVANS SM, LORD EM: Oxygen dependence of the cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-y1)-1V(2,2,3,3,3-pentafluoropropy0 acetamidel: analy-sis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer (1995) 72:869–874.
   PubMed Web of Science ®Google Scholar
• WALEH NS, BRODY MD, KNAPP MA et al: Mapping of the vascular endothelial growth factor-producing hy-poxic cells in multicellular spheroids using a hypoxia specific marker. Cancer Res. (1995) 55:6222–6226.
   PubMed Web of Science ®Google Scholar
• EVANS SM, JOINER B, JENKINS WT et al: Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-y1)-N-(2,2,3,3,3-pentafluoropropy0 acetamideb Br. J. Cancer (1995) 72:875–882.
   Web of Science ®Google Scholar
• EVANS SM, JENKINS WT, JOINER B, LORD EM, KOCH CJ: 2 - nitroimidazole (EF5) binding predicts radiation resis-tance in individual 9L s.c. tumours. Cancer Res. (1996) 56:405-411. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(6)
   Google Scholar
• LEE J, SIEMANN DW, KOCH CJ, LORD EM: Direct relation-ship between radiobiological hypoxia in tumours and monoclonal antibody detection of EF5 cellular ad-ducts. Int. J. Cancer (1996) 67:372–378.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN KM, EVANS SM, JENKINS WT et al: Biodistri-bution of the nitroimidazole EF5 [2-(2-nitro-1H-imidazol-1-y1)-N-(2,2,3,3,3-pentafluoropropyl) aceta-mide] in mice bearing subcutaneous EMT6 tumours. J. Pharmacol. Exp. Ther. (1996) 277:1049–1057.
   PubMed Web of Science ®Google Scholar
• EVANS SM, JENKINS WT, SHAPIRO M, KOCH CJ: Evalua-tion of the concept of "hypoxic fraction" as a descrip-tor of tumour oxygenation status. Adv. Exp. Med. Biol. (1997) 411:215–225.
   PubMed Web of Science ®Google Scholar
• MEHTA LK, MONNEY H, PARRICK J, HODGKISS RJ: Poten-tial bioreductively activated hypoxia probes and post irradiation radiosensitizers related to NITP. AntiCancer Drug Des. (1995) 10:227–241.
   PubMedGoogle Scholar
• HOD GKISS RJ, WEBSTER L, WILSON GD: Development of bioreductive markers for tumour hypoxia. Acta Gnat]. (1995) 34:351–355.
   Google Scholar
• KENNEDY AS, RALEIGH JA, PEREZ GM et al: Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohisto-chemical assays. Int. J. Radial Oncol. Biol. Phys. (1997) 37:897–905.
   Web of Science ®Google Scholar
• EVANS SM, LAUGHLIN KM, PUGH CR, SEHGAL CM, SAUN-DERS HM: Use of power doppler ultrasound guided bi-opsies to locate regions of tumour hypoxia. Br. J. Cancer (1997) 76:1308–1314.
   PubMed Web of Science ®Google Scholar
• CHAPLIN DJ: Hydralazine induced tumour hypoxia: a potential target for cancer chemotherapy. J. Natl Can-cer Inst. (1989) 81:618–622.
   PubMed Web of Science ®Google Scholar
• BREMNER JCM, STRATFORD IJ, BOWLER J, ADAMS GE: Bioreductive drugs and the selective induction of tu-mour hypoxia. Br. J. Cancer (1990) 61:717–721.
   PubMed Web of Science ®Google Scholar
• BUTLER SA, WOOD PJ, COLE sincerely et al.: Enhance-ment of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br. J. Cancer (1997) 76:438–444.
   PubMed Web of Science ®Google Scholar
• HILL SA, SAMPSON LE, CHAPLIN DJ: Anti-vascular ap-proaches to solid tumour therapy: evaluation of vin-blastine and flavone acetic acid. Int. J. Cancer (1995) 63:119–123.
   PubMed Web of Science ®Google Scholar
• CHAPLIN DJ, PETTIT GR, PARKINS CS, HILL SA: Antivas-cular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer (1996) 74 (Suppl. XXVII) :S86–S88.
   Google Scholar
• FUKUMURA D, JAIN RK: Role of nitric oxide in angio-genesis and microcirculation in tumours. Cancer Met. Rev. (1998) 17:77–89.
   PubMed Web of Science ®Google Scholar
• WOOD PJ, STRATFORD IJ, ADAMS GE, SZABO C, VANE JR: Modification of energy metabolism and radiation re-sponse of a murine tumour by changes in nitric oxide availability. Biochem. Biophys. Res. Comm. (1993) 192:505–510.
   PubMed Web of Science ®Google Scholar
• WOOD PJ, SAMSON JM, BUTLER SA et al.: Induction of hypoxia in experimental tumours by the nitric oxide synthase inhibitor NO-nitro-L-arginine. Cancer Res. (1994) 54:6458–6463.
   PubMed Web of Science ®Google Scholar
• WOOD SA, SANSON JM, STRATFORD IJ et al: Modifica-tion of metabolism in transplantable and spontaneous tumours by the nitric oxide synthase inhibitor nitro-L-arginine. Int. J. RadiaL Oncol. Biol. Phys. (1994) 29:443–447.
   Web of Science ®Google Scholar
• HORSMAN MR, CHAPLIN DJ, HILL SA et al Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br. J. Cancer. (1996) 74 (Suppl XXVII) S168–S171
   Google Scholar
• CLIFFE S, TAYLOR ML, RUTLAND M et al.: Combining bioreductive drugs (SR 4233 or SN 23862) with the va-soactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int. J. RadiaL Oncol. Biol. Phys. (1995) 29:373–377.
   Web of Science ®Google Scholar
• WILSON WR, PRUIJN FB: Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing. Clin. Exp. Pharmacol. Physic)]. (1995) 22:881–885.
   PubMed Web of Science ®Google Scholar
• BIBBY MC, SLEIGH NR, LOADMAN P, DOUBLE JA: Poten-tiation of E09 anti-tumour activity by hydralazine. Eur. J. Cancer (1993) 29A:1033–1035.
   PubMed Web of Science ®Google Scholar
• CHAPLIN DJ, ACKER B: Potentiation of RSU 1069 tumour cytotoxicity by hydralazine: a new approach to selec-tive therapy. Int. J. Radial Oncol. Biol. Phys. (1987) 13:579–585.
   Google Scholar
• HONESS DY, BLEEHEN NM: Effects of two tumour blood flow modifiers in KHT tumours and normal tissues in mice. Int. J. RadiaL Bid (1991) 60:249–253.
   PubMed Web of Science ®Google Scholar
• FIELD SB, NEEDHAM S, BURNEY IA et al .: Differences in vascular response between primary and transplanted tumours. Br. J. Cancer (1991) 63:723–726.
   PubMed Web of Science ®Google Scholar
• COWEN SE, BIBBY MC, DOUBLE JA: Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncologica (1995) 34:357–360.
   PubMed Web of Science ®Google Scholar
• VAN GEEL IP, OPPELAAR H, RIJKEN PF et al.: Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br. J. Cancer (1996) 73:288–293.
   PubMed Web of Science ®Google Scholar
• BAAS P, OPPELAAR H, STAVENUITER M, ZANDWIJK N, STEWART FA: Interaction of the bioreductive drug (SR 4233) and photodynamic therapy using photofrin II in a mouse tumour model. Int. J. Radial Biol. Oncol. Phys. (1993) 27:665–670.
   PubMed Web of Science ®Google Scholar
• BAAS P, OPPELAAR H, MICHIELSEN C, ZANDWIJK N, STEWART FA: Enhancement of interstitial photody-namic therapy by mitomycin C and E09 in a mouse tu-mour model. Int. J. Cancer (1994) 56:880–885.
   PubMed Web of Science ®Google Scholar
• BREMNER JC, ADAMS GE, PEARSON JK et al.: Increasing the effect of photodynamic therapy on the RIF-lmurine sarcoma using the bioreductive drugs RSU 1069 and RB 6145. Br. J. Cancer (1992) 66:1070–1076.
   PubMed Web of Science ®Google Scholar
• BREMNER JC, BRADLEY JK, ADAMS GE et al.: Comparing the anti-tumour effect of several bioreductive drugs when used in combination with photodynamic ther-apy (PDT). Int. J. RadiaL Oncol. Biol. Phys. (1994) 29:329–332.
   Web of Science ®Google Scholar
• MA LW, MOAN J, STEEN HB, IANI V: Anti-tumour activity of photodynamic therapy in combination with mito-mycin C in nude mice with human colon adenocarci-noma. Br. J. Cancer. (1995) 71:950–956.
   PubMed Web of Science ®Google Scholar
• VAN GEEL IP, OPPELAAR H, OUSSOREN YG, SCHUIT-MAKER JJ, STEWART FA: Mechanisms for optimising photodynamic therapy: second generation photosen-sitizers in combination with mitomycin C. Br. J. Cancer (1995) 72:344–350.
   PubMed Web of Science ®Google Scholar
• DATTA SN, ALLMAN R, LOH C, MASON M, MATTHEWS PN: Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cell line. Br. J. Cancer (1997) 76:312–317.
   PubMed Web of Science ®Google Scholar
• CHO YH, STRAIGHT RC, SMITH JA: Effects of photody-namic therapy in combination with intravesical drugs in a murine bladder tumour model. J. Urol. (1992) 147:743–746.
   PubMed Web of Science ®Google Scholar
• MA LW, MOAN J, BERG K, PENG Q, STEEN HB: Potentia-tion of photodynamic therapy in cultured human co-lon adenocarcinoma cells. RadiaL Res. (1993) 134:22–28.
   PubMed Web of Science ®Google Scholar
• BAAS P, VAN GEEL IP, OPPELAAR H et al: Enhancement of photodynamic therapy by mitomycin C: a preclini-cal and clinical study. Br. J. Cancer. (1996) 73:945–951.
   PubMed Web of Science ®Google Scholar
• MYERS TG, WEINSTEIN JN, WORKMAN Pet al Statistical contribution of DT-diaphorase and other molecular targets to cell line selective activity patterns observed for compounds tested in the NCI anticancer drug screen. Proc. Am. Assoc. Cancer Res. (1998) 39:429.
   Google Scholar
• CUMMINGS J, SPANSWICK VJ, GARDINER J, RITCHIE A, SMYTH JF: Pharmacological and biochemical determi-nants of the antitumour activity of the indoloquinone E09. Biochem. Pharmacol (1998) 55:253–260.
   PubMed Web of Science ®Google Scholar
• COWAN DSM, HICKS KO, WILSON WR: Multicellular membranes as an in vitro model for extravascular dif-fusion in tumours. Br. J. Cancer (1996) 74 (Suppl. XXVII) :S28–S31.
   Google Scholar
• COLLINGRIDGE DR, YOUNG WK, VOJNOVIC B et al.: Measurement of tumour oxygenation: a comparison between polarographic needle electrodes and a time resolved luminescence-based optical sensor. Radiat. Res. (1997) 147:329–334.
   PubMed Web of Science ®Google Scholar
• VELCULESCU VE, ZHANG L, VOGELSTEIN B, KINZLER KW: Serial analysis of gene expression. Science (1995) 270:484–487.
   PubMed Web of Science ®Google Scholar
• DACHS GU, DOUGHERTY GS, STRATFORD IJ, CHAPLIN DJ: Targeting gene therapy to cancer: a review. Oncol Res. (1997) 9:313–325.
   PubMed Web of Science ®Google Scholar
• SAUNDERS MP, PATTERSON AV, RATCLIFFE PJ, HARRIS AL, STRATFORD IJ: Using gene therapy to selectively ac-tivate bioreductive drugs in tumours. Proc. Am. Assoc. Cancer Res. (1998) 39:513.
   Google Scholar